• Publication Date: 10/01/2019
  • Author(s):
    Bordes-Picard, Frédérique Chiou, Herbert Mercuri, Salvatore
  • Organization(s):
  • Article Type: Technical Articles
  • Subjects: Capsules and Blisters, Devices and Components, Outsourcing, Product Development/Formulation
Developers must carefully evaluate the device, formulation and capsule, as well as the interactions among them.

Because DPIs are a drug/device combination product, there are three critical components within the overall product that developers must select and evaluate: the device, the formulation and (when using a capsule-based inhaler) the capsule itself. These components form what may be called “the DPI interaction triangle.” Using a risk-based approach that ensures the appropriate technologies are selected for the three components can be the best path to success.

Download PDF